Lisata Therapeutics, Inc. (LSTA)
(Delayed Data from NSDQ)
$2.94 USD
+0.01 (0.36%)
Updated Aug 6, 2024 03:39 PM ET
After-Market: $3.00 +0.06 (2.02%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth C Momentum F VGM
Income Statements
Fiscal Year end for Lisata Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 0 | 0 | 0 | 0 | 0 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 0 | 0 | 0 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 26 | 58 | 29 | 19 | 20 |
Income After Depreciation & Amortization | -26 | -58 | -29 | -19 | -20 |
Non-Operating Income | 3 | 1 | 0 | 0 | 1 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | -23 | -57 | -29 | -19 | -19 |
Income Taxes | -2 | -2 | -2 | -11 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -21 | -54 | -27 | -8 | -19 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -21 | -54 | -27 | -8 | -19 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -26 | -57 | -26 | -19 | -20 |
Depreciation & Amortization (Cash Flow) | -1 | 1 | 3 | 0 | 0 |
Income After Depreciation & Amortization | -26 | -58 | -29 | -19 | -20 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 8.07 | 5.18 | 3.69 | 1.03 | 0.69 |
Diluted EPS Before Non-Recurring Items | -2.58 | -4.07 | -7.50 | -20.39 | -28.19 |
Diluted Net EPS (GAAP) | -2.58 | -10.47 | -7.50 | -7.95 | -28.19 |
Fiscal Year end for Lisata Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Cost Of Goods | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | NA | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 6.60 | 6.02 | 5.96 | 6.87 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -6.60 | -6.02 | -5.96 | -6.87 |
Non-Operating Income | NA | 0.40 | 0.66 | 0.70 | 0.52 |
Interest Expense | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | NA | -6.20 | -5.37 | -5.26 | -6.36 |
Income Taxes | NA | -0.80 | 0.00 | 0.00 | -2.33 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -5.40 | -5.37 | -5.26 | -4.03 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -5.40 | -5.37 | -5.26 | -4.03 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | NA | 8.29 | 8.13 | 8.14 | 8.02 |
Diluted EPS Before Non-Recurring Items | NA | -0.65 | -0.66 | -0.65 | -0.50 |
Diluted Net EPS (GAAP) | NA | -0.65 | -0.66 | -0.65 | -0.50 |